IL-6 Directed Therapy in Transplantation.

Area of Science:

• Immunology
• Transplantation Biology
• Inflammation Research

Background:

• Interleukin-6 (IL-6) is a key pro-inflammatory cytokine implicated in acute and chronic rejection following solid organ transplantation.
• IL-6 contributes to allograft injury through various mechanisms, including promoting inflammation, adaptive immunity, innate immune responses, and fibrosis.
• Experimental studies demonstrate that inhibiting IL-6/IL-6 receptor (IL-6R) signaling can mitigate transplant rejection.

Purpose of the Study:

• To review the experimental evidence for IL-6/IL-6R signaling inhibition in transplantation.
• To discuss the current clinical applications of IL-6/IL-6R signaling blockade for allograft injury.
• To highlight the potential of IL-6 signaling inhibition as a therapeutic strategy in solid organ transplantation.

Main Methods:

• Review of experimental studies on IL-6 and allograft injury.
• Analysis of clinical trial data for IL-6/IL-6R signaling inhibitors.
• Examination of available therapeutic agents targeting the IL-6 pathway.

Main Results:

• IL-6 promotes acute phase reactions, B cell maturation, antibody formation, cytotoxic T-cell differentiation, and inhibits regulatory T-cell development.
• Blockade of IL-6/IL-6R signaling has shown efficacy in experimental models of kidney and heart transplant rejection.
• Tocilizumab (anti-IL-6R mAb) has demonstrated promising initial results in clinical trials for kidney transplant desensitization and antibody-mediated rejection (AMR).

Conclusions:

• IL-6/IL-6R signaling inhibition represents a novel therapeutic approach for preventing and treating allograft injury.
• Clinical evidence supports the use of IL-6 blockade for desensitization and AMR treatment in kidney transplant recipients.
• Further clinical trials are necessary to establish the role of IL-6 signaling inhibition in other solid organ transplantations.